Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis
The induction of immunologic tolerance is an important clinical goal in autoimmunity. CD4+ regulatory T (Treg) cells, defined by the expression of the transcription factor forkhead box P3 (FoxP3), play a central role in the control of autoimmune responses. Quantitative and qualitative defects of Tre...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Neurology Research International |
| Online Access: | http://dx.doi.org/10.1155/2011/256460 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548087661330432 |
|---|---|
| author | Wassim Elyaman Samia J. Khoury David W. Scott Anne S. De Groot |
| author_facet | Wassim Elyaman Samia J. Khoury David W. Scott Anne S. De Groot |
| author_sort | Wassim Elyaman |
| collection | DOAJ |
| description | The induction of immunologic tolerance is an important clinical goal in autoimmunity. CD4+ regulatory T (Treg) cells, defined by the expression of the transcription factor forkhead box P3 (FoxP3), play a central role in the control of autoimmune responses. Quantitative and qualitative defects of Tregs have been postulated to contribute to failed immune regulation in multiple sclerosis (MS) and other autoimmune diseases. This paper highlights the potential uses of T regulatory cell epitopes (Tregitopes), natural Treg epitopes found to be contained in human immunoglobulins, as immunomodulating agents in MS. Tregitopes expand Treg cells and induce “adaptive Tregs” resulting in immunosuppression and, therefore, are being considered as a potential therapy for autoimmune diseases. We will compare Tregitopes versus intravenous immunoglobulin (IVIg) in the treatment of EAE with emphasis on the potential applications of Tregitope for the treatment of MS. |
| format | Article |
| id | doaj-art-ce2bf5b56edf433694ac1fa7c4ef12fd |
| institution | Kabale University |
| issn | 2090-1852 2090-1860 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neurology Research International |
| spelling | doaj-art-ce2bf5b56edf433694ac1fa7c4ef12fd2025-02-03T06:42:16ZengWileyNeurology Research International2090-18522090-18602011-01-01201110.1155/2011/256460256460Potential Application of Tregitopes as Immunomodulating Agents in Multiple SclerosisWassim Elyaman0Samia J. Khoury1David W. Scott2Anne S. De Groot3Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, NRB 641, Boston, MA 02115, USACenter for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, NRB 641, Boston, MA 02115, USAUniformed Services University of the Health Sciences, Bethesda, MD 20814, USAEpiVax Inc., University of Rhode Island, Providence, RI 02903, USAThe induction of immunologic tolerance is an important clinical goal in autoimmunity. CD4+ regulatory T (Treg) cells, defined by the expression of the transcription factor forkhead box P3 (FoxP3), play a central role in the control of autoimmune responses. Quantitative and qualitative defects of Tregs have been postulated to contribute to failed immune regulation in multiple sclerosis (MS) and other autoimmune diseases. This paper highlights the potential uses of T regulatory cell epitopes (Tregitopes), natural Treg epitopes found to be contained in human immunoglobulins, as immunomodulating agents in MS. Tregitopes expand Treg cells and induce “adaptive Tregs” resulting in immunosuppression and, therefore, are being considered as a potential therapy for autoimmune diseases. We will compare Tregitopes versus intravenous immunoglobulin (IVIg) in the treatment of EAE with emphasis on the potential applications of Tregitope for the treatment of MS.http://dx.doi.org/10.1155/2011/256460 |
| spellingShingle | Wassim Elyaman Samia J. Khoury David W. Scott Anne S. De Groot Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis Neurology Research International |
| title | Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis |
| title_full | Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis |
| title_fullStr | Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis |
| title_full_unstemmed | Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis |
| title_short | Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis |
| title_sort | potential application of tregitopes as immunomodulating agents in multiple sclerosis |
| url | http://dx.doi.org/10.1155/2011/256460 |
| work_keys_str_mv | AT wassimelyaman potentialapplicationoftregitopesasimmunomodulatingagentsinmultiplesclerosis AT samiajkhoury potentialapplicationoftregitopesasimmunomodulatingagentsinmultiplesclerosis AT davidwscott potentialapplicationoftregitopesasimmunomodulatingagentsinmultiplesclerosis AT annesdegroot potentialapplicationoftregitopesasimmunomodulatingagentsinmultiplesclerosis |